Cancer affects millions. It cuts across languages, cultures, and family histories. As a cancer community we do what we can. But there’s always that question ringing in our ears, “could we do more?”
The Exact Sciences’ pipeline is expanding at a rapid pace. We’re taking the same innovative problem-solving approach that resulted in the multitarget stool DNA test (Cologuard) to tackle a wide array of cancer screening challenges. We’re also leveraging the success and impact of the Oncotype IQ portfolio of tests to transform patient treatment decisions. Through our pipeline efforts, we aim to give patients and physicians confidence, while helping to provide smart answers at every step of the cancer journey.
Exact Sciences and Genomic Health have teamed up to take cancer on, together. By combining our leading portfolio of products, we are continuing our relentless pursuit of earlier detection and smarter answers.